Introduction: Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient's clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor. Areas covered: The aim of this manuscript is to review current literature on the effectiveness and safety of deucravacitinib in psoriasis to offer readers a wide perspective. The current English literature was analyzed using the PubMed, Google Scholar, Embase, Cochrane Skin, and clinicaltrials.gov databases, selecting the most relevant manuscripts. Expert opinion: Deucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approach required for the treatment of this disease.

Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation / Potestio, Luca; Tommasino, Nello; Lauletta, Giuseppe; Feo, Federica; Ruggiero, Angelo; Martora, Fabrizio; Portarapillo, Antonio; Guerriero, Luigi; Megna, Matteo. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2024). [10.1080/14740338.2024.2351462]

Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation

Potestio, Luca;Tommasino, Nello;Lauletta, Giuseppe;Feo, Federica;Ruggiero, Angelo;Martora, Fabrizio;Portarapillo, Antonio;Guerriero, Luigi;Megna, Matteo
2024

Abstract

Introduction: Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient's clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor. Areas covered: The aim of this manuscript is to review current literature on the effectiveness and safety of deucravacitinib in psoriasis to offer readers a wide perspective. The current English literature was analyzed using the PubMed, Google Scholar, Embase, Cochrane Skin, and clinicaltrials.gov databases, selecting the most relevant manuscripts. Expert opinion: Deucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approach required for the treatment of this disease.
2024
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation / Potestio, Luca; Tommasino, Nello; Lauletta, Giuseppe; Feo, Federica; Ruggiero, Angelo; Martora, Fabrizio; Portarapillo, Antonio; Guerriero, Luigi; Megna, Matteo. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2024). [10.1080/14740338.2024.2351462]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/959153
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact